1. Home
  2. BROS vs ABVX Comparison

BROS vs ABVX Comparison

Compare BROS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dutch Bros Inc.

BROS

Dutch Bros Inc.

HOLD

Current Price

$51.19

Market Cap

7.7B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$124.72

Market Cap

9.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BROS
ABVX
Founded
1992
2013
Country
United States
France
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
9.2B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BROS
ABVX
Price
$51.19
$124.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
18
11
Target Price
$77.22
$130.09
AVG Volume (30 Days)
5.6M
984.0K
Earning Date
02-12-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
56.73
N/A
EPS
0.51
N/A
Revenue
$1,537,335,000.00
$6,231,374.00
Revenue This Year
$28.88
$6.80
Revenue Next Year
$25.68
N/A
P/E Ratio
$105.78
N/A
Revenue Growth
28.93
N/A
52 Week Low
$47.16
$4.77
52 Week High
$86.88
$148.83

Technical Indicators

Market Signals
Indicator
BROS
ABVX
Relative Strength Index (RSI) 34.46 57.47
Support Level $51.77 $115.93
Resistance Level $57.50 $116.72
Average True Range (ATR) 2.93 5.06
MACD -0.40 1.15
Stochastic Oscillator 9.58 95.24

Price Performance

Historical Comparison
BROS
ABVX

About BROS Dutch Bros Inc.

Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: